ReviewExpert opinion on investigational drugs2017
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.
Review in Expert opinion on investigational drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Combination of PSMA targeting alpha-emitting radioligand [Medical oncology (Northwood, London, England) · 2025Article
- Transcription Factors and Methods for the Pharmacological Correction of Their Activity.International journal of molecular sciences · 2025Review
- TET2 gene mutation status associated with poor prognosis of transition zone prostate cancer: a retrospective cohort study based on whole exome sequencing and machine learning models.Frontiers in endocrinology · 2025Article
- Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer.Translational cancer research · 2024Article
- Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR.Mini reviews in medicinal chemistry · 2024Review
- Molecular complexity of intraductal carcinoma of the prostate.Cancer medicine · 2024Review
- Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.Cancer research communications · 2022Article
- Article
- Article
- Getting a handle on chemical probes of chomatin readers.Future medicinal chemistry · 2021Article
- Dysregulated Transcriptional Control in Prostate Cancer.International journal of molecular sciences · 2019Review
- Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.Medicinal research reviews · 2019Review
- Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.Frontiers in pharmacology · 2019Review
- Recent Advances in Prostate Cancer Treatment and Drug Discovery.International journal of molecular sciences · 2018Review
- PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.Expert review of clinical pharmacology · 2018Review
- Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.F1000Research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionThe bromodomain and extra-terminal (BET) family of proteins are epigenetic readers of acetylated histones regulating a vast network of protein expression across many different cancers. Therapeutic targeting of BET is an attractive area of clinical development for metastatic castration-resistant prostate cancer (mCRPC), particularly due to its putative effect on c-MYC expression and its interaction with the androgen receptor (AR). Areas covered: We speculate that a combination approach using inhibitors of BET proteins (BETi) with other targeted therapies may be required to improve the therapeutic index of BET inhibition in the management of prostate cancer. Preclinical data has identified several molecular targets that may enhance the effect of BET inhibition in the clinic. This review will summarize the known preclinical data implicating BET as an important therapeutic target in advanced prostate cancer, highlight the ongoing clinical trials targeting this protein family, and speculate on rationale combination strategies using BETi together with other agents in prostate cancer. A literature search using Pubmed was performed for this review. Expert opinion: Use of BETi in the treatment of mCRPC patients may require the addition of a second novel agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.